6/24/2025

Despite Revvity’s underperformance relative to the Dow over the past year, Wall Street analysts are moderately optimistic about its prospects.

Source: Yahoo

6/20/2025

Key Insights Using the 2 Stage Free Cash Flow to Equity, Revvity fair value estimate is US$154 Revvity is estimated to...

Source: Yahoo

6/18/2025

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Source: Yahoo

6/17/2025

Revvity Inc. stock outperforms competitors despite losses on the day

Source: MarketWatch

6/16/2025

Revvity Inc. stock outperforms competitors on strong trading day

Source: MarketWatch

6/13/2025

Revvity Inc. stock underperforms Friday when compared to competitors

Source: MarketWatch

6/10/2025

Presenter SpeechMatthew Sykes Good morning, everyone. I'm Matt Sykes, the life science tools and diagnostics analyst at Goldman Sachs. I have the pleasure of welcoming Prahlad Singh, the CEO of...

Source: Finnhub

6/5/2025

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Source: Yahoo

6/4/2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.3%. This performance was noticeably worse than the S&P 500’s 1.9% fall.

Source: Yahoo

6/2/2025

West Pharmaceutical Services, Inc.'s lumpy performance, declining profits & high valuation raise concerns. Click for why WST is rated Hold and not upgraded.

Source: SeekingAlpha

6/2/2025

Revvity Inc. stock underperforms Monday when compared to competitors

Source: MarketWatch

6/2/2025

WALTHAM, Mass., June 02, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference standards have undergone appropriate design controls to meet U.S. Food and Drug Administration (FDA) regulatory requirem

Source: Yahoo

6/2/2025

Revvity, Inc. announced the launch of three Mimix reference standards for IVD use, designed for monitoring of next-generation sequencing or droplet digital polymerase chain reacting assays designed...

Source: Finnhub

5/30/2025

Revvity (NYSE:RVTY) has had a rough three months with its share price down 18%. We, however decided to study the...

Source: Yahoo

5/23/2025

Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.

Source: Yahoo

5/23/2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Source: Yahoo

5/19/2025

WALTHAM, Mass., May 19, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings.

Source: Yahoo

5/15/2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

Source: Yahoo

5/14/2025

The S&P 500 ticked 0.1% higher on Wednesday, May 14, 2025, bolstered by a tech sector rally even as macroeconomic concerns pressured other sectors.

Source: Yahoo

5/14/2025

Revvity Inc. stock underperforms Wednesday when compared to competitors

Source: MarketWatch